| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966871 | Vaccine | 2012 | 8 Pages |
Abstract
⺠We assess the cost-effectiveness of an additional birth dose of Hepatitis B vaccine. ⺠The birth dose is highly cost-effective with an ICER of 250.95 US$ per DALY averted. ⺠Outcome shows sensitive to parameter variation in sensitivity analysis. ⺠Most sensitive to 'prevalence of HBV' and 'transition probability from chronic HBV to liver cancer'.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Corinna Klingler, Andrea I. Thoumi, Vinod S. Mrithinjayam,